文献速递MDS 与骨髓增殖性肿瘤白血病

胚系DDX41突变定义成人MDS/AML中的重要亚群

Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
PubMed 文献 · Blood · 2019-01-01

在1385例未选择的MDS或AML成人患者中,靶向测序检出43例携带胚系DDX41变异,其中33例为致病性变异,占队列2.4%。这些患者多为男性(79%),中位年龄69岁,仅27%有家族史,85%核型正常,79%伴第二个体细胞DDX41突变;高危患者接受强化化疗或阿扎胞苷的总体缓解率分别为100%和73%,中位总生存5.2年。

要点

  • 成人MDS/AML中胚系DDX41致病性变异占2.4%,多无家族史。
  • DDX41相关髓系肿瘤以男性为主,常伴既往血细胞减少和第二个DDX41突变。
  • 高危患者接受强化化疗或阿扎胞苷缓解率高,中位总生存5.2年。

核心结论

  • 胚系DDX41突变在成人MDS/AML中相对常见,常无已知家族史,支持系统筛查。

研究设计与样本

  • 在1385例未选择的MDS或AML患者中,采用靶向下一代测序分析胚系DDX41变异。

主要发现

  • 43例无关患者检出28种胚系DDX41变异,其中21种为致病性、7种意义不明。
  • 33例携带致病性变异患者占队列2.4%,中位年龄69岁,男性占79%。
  • 仅9例(27%)有血液恶性肿瘤家族史,15例(46%)在诊断前数年有血细胞减少史。
  • 85%患者核型正常,79%患者存在第二个体细胞DDX41突变。
  • 高危患者强化化疗(n=9)或阿扎胞苷(n=11)的总体缓解率分别为100%和73%,中位总生存5.2年。

关键数值与推荐

  • 胚系DDX41致病性变异占未选择成人MDS/AML队列的2.4%。
  • 高危DDX41相关MDS/AML患者强化化疗后总体缓解率100%,阿扎胞苷后73%。
  • 中位总生存5.2年。

临床怎么用

  • 对成人MDS/AML患者考虑系统筛查胚系DDX41突变,即使无家族史。
  • 识别DDX41相关髓系肿瘤特征:男性、既往血细胞减少、第二个DDX41突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Germline DDX41 mutations are involved in familial myelodysplastic syndromes (MDSs) and acute myeloid leukemias (AMLs). We analyzed the prevalence and characteristics of DDX41-related myeloid malignancies in an unselected cohort of 1385 patients with MDS or AML. Using targeted next-generation sequencing, we identified 28 different germline DDX41 variants in 43 unrelated patients, which we classified as causal (n = 21) or unknown significance (n = 7) variants. We focused on the 33 patients having causal variants, representing 2.4% of our cohort. The median age was 69 years; most patients were men (79%). Only 9 patients (27%) had a family history of hematological malignancy, and 15 (46%) had a personal history of cytopenia years before MDS/AML diagnosis. Most patients had a normal karyotype (85%), and the most frequent somatic alteration was a second DDX41 mutation (79%). High-risk DDX41 MDS/AML patients treated with intensive chemotherapy (n = 9) or azacitidine (n = 11) had an overall response rate of 100% or 73%, respectively, with a median overall survival of 5.2 years. Our study highlights that germline DDX41 mutations are relatively common in adult MDS/AML, often without known family history, arguing for systematic screening. Salient features of DDX41-related myeloid malignancies include male preponderance, frequent preexisting cytopenia, additional somatic DDX41 mutation, and relatively good outcome.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sébert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019. PMID: 31484648. doi:10.1182/blood.2019000909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。